JPMorgan raised the firm’s price target on Veeva (VEEV) to $249 from $218 and keeps a Neutral rating on the shares. Veeva has a substantial addressable market at roughly $20B, and the company has seen robust revenue growth of 28% over the past five years, the growth profile has slowed, with the company generating more than 30% EBITDA growth over the past five years, and the multiple should appropriately reflect this, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva Systems Announces Board Member Retirement
- Veeva, Boehringer Ingelheim partner to launch ‘One Medicine Platform’
- Veeva Systems: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Veeva Systems’ Earnings Call Highlights Strong Growth and Strategic Wins
- Veeva price target raised to $245 from $240 at Scotiabank